Cadila Healthcare Q3 Review - Strong Domestic Growth Partly Offset By U.S. Decline: ICICI Direct
Brightly coloured pharmaceutical medication. (Photographer: Chris Ratcliffe/Bloomberg)

Cadila Healthcare Q3 Review - Strong Domestic Growth Partly Offset By U.S. Decline: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Cadila Healthcare Ltd.’s Q3 FY21 revenues grew 4.3% YoY to Rs 3,796 crore (our estimate Rs 3,906 crore).

Domestic formulations posted strong growth of 21.2% YoY to Rs 1,104 crore. However, U.S. sales declined 4.3% YoY to Rs 1,603 crore.

Wellness segment also grew a robust 15.8% YoY to Rs 376 crore. Emerging markets grew 10.9% YoY to Rs 293 crore.

Active pharmaceutical ingredient segment de-grew 18.8% YoY to Rs 132 crore. Animal health segment grew 17.0% YoY to Rs 163 crore.

Ebitda margins expanded 220 basis points YoY to 21.3% (our estimate 21.2%) due to a better overall operational performance.

Click on the attachment to read the full report:

ICICI Direct Cadila Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.